Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
Year: 2025
Type: article
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia evolving from MDS (sAML) [ 1 ]. Multiple factors are reported to influence the prognosis of patients with MDS and sAML undergoing allo-HSCT, including prognostic stratification, disease status, conditioning regimen and pre-transplant therapy [ 2 , 3 ]. Our randomized controlled trial (RCT) has shown that granulocyte-colony stimulating factor, decitabine, busulfan and cyclophosphamide (G-DAC-BuCy) conditioning is a better choice than busulfan and cyclophosphamide (BuCy) conditioning for patients with MDS-refractory anemia with excess blasts (RAEB) or sAML undergoing allo-HSCT [ 4 ].
Source: Blood Cancer Journal
Institutions: Nanfang Hospital, Southern Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Peking University People's Hospital, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Chenzhou First People's Hospital, Fourth Affiliated Hospital of Guangxi Medical University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
OpenAlex ID: W4407732004